NOVACARDIA, INC. INDEMNITY AGREEMENTIndemnity Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations • Delaware
This Indemnity Agreement (this "Agreement") dated as of , 20 , is made by and between NovaCardia, Inc., a Delaware corporation (the "Company"), and ("Indemnitee").
LICENSE AGREEMENTLicense Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations
WHEREAS, Licensor has good experience in the research and development of pharmaceutical products and owns valuable technical knowledge, know-how and inventions, patentable or not, including but not limited to the proprietary pharmaceutical compound referred to as K201;
Supplementary Agreement to the License Agreement dated September 1, 2006 between Aetas and NovaCardiaSupplementary Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations
With reference to the license agreement ("License Agreement") for K201 dated September 1, 2006 by and between Aetas Pharma Co., Ltd. ("Licensor") and NovaCardia Inc. ("Licensee"), Licensor and Licensee hereby enter into this Supplementary Agreement ("Supplementary Agreement") as of January 5, 2007 in order to supplement and amend the License Agreement to incorporate the Products for oral administration further to the existing intravenous administration.
DSM PHARMA CHEMICALS, INC. and NOVACARDIA, INC. DEVELOPMENT, TECHNOLOGY TRANSFER AND PRE-COMMERCIAL MANUFACTURING AGREEMENTDevelopment, Technology Transfer and Pre-Commercial Manufacturing Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT, TECHNOLOGY TRANSFER AND PRE-COMMERCIAL MANUFACTURING AGREEMENT (the "Agreement") is executed as of this 5th day of June, 2006 (the "Effective Date"), by and between DSM Pharma Chemicals North America, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 45 Waterview Blvd., Parsippany, NJ 07054, and its affiliate, DSM Fine Chemicals Austria Nfg GmbH Co KG, an Austrian corporation, having a place of business at St. Peter Strasse 25, 4021 Linz, Austria (collectively, both DSM parties hereinafter referred to as "DPC"); and NovaCardia, Inc.("NovaCardia"), a corporation organized under the laws of Delaware, having its principal place of business at 12230 El Camino Real, Suite 300, San Diego, California 92130.
LICENSE AGREEMENTLicense Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations
This Agreement made and entered into by and between KYOWA HAKKO KOGYO CO., LTD., a Japanese corporation having its principal offices at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (hereinafter referred to as "KH") and NOVACARDIA, INC., a Delaware corporation having its principal offices at 12230 El Camino Real, Suite 300, San Diego, California, 92130, United States of America (hereinafter referred to as "NC").
NOVACARDIA, INC. AMENDMENT No. 1 TO AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENTInvestors' Rights Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT (the "Amendment") is made as of March 21, 2007, by and among NOVACARDIA, INC., a Delaware corporation (the "Company"), the holders of Series A Preferred Stock of the Company ("Series A Preferred") as listed on Exhibit A to the Investors' Rights Agreement (as defined below) (the "Series A Holders"), the holders of the Series B Preferred Stock of the Company ("Series B Preferred") as listed on Exhibit B to the Investors' Rights Agreement (the "Series B Holders"), Lighthouse (as defined in the Investors' Rights Agreement), TriplePoint Capital ("TriplePoint") and the Follow-On Series B Holders (as defined below) (the Series A Holders, the Series B Holders and the Follow-On Series B Holders are collectively referred to herein as the "Investors" and each individually referred to herein as an "Investor").
MASTER CLINICAL SERVICES AGREEMENTMaster Clinical Services Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations
As a condition of participating as a clinical investigator in the protocol entitled, " " (the "Study") sponsored by NovaCardia, Inc. ("NovaCardia"), please provide the appropriate information and responses to the following statements.
